Michael P Simons

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7347609/publications.pdf

Version: 2024-02-01

372 papers	37,940 citations	1994 101 h-index	3487 182 g-index
431 all docs	431 docs citations	431 times ranked	33520 citing authors

#	Article	IF	Citations
1	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Science Translational Medicine, 2022, 14, eabj7521.	12.4	71
2	Endotheliumâ€derived lactate is required for pericyte function and bloodâ€“brain barrier maintenance. EMBO Journal, 2022, 41, e109890.	7.8	27
3	Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells inÂvitro and inÂvivo. Journal of Hepatology, 2022, 77, 723-734.	3.7	24
4	Imaging and Analysis of Oil Red O-Stained Whole Aorta Lesions in an Aneurysm Hyperlipidemia Mouse Model. Journal of Visualized Experiments, 2022, , .	0.3	0
5	Syndecan-2 selectively regulates VEGF-induced vascular permeability. , 2022, 1, 518-528.		10
6	FGFR1 SUMOylation coordinates endothelial angiogenic signaling in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	16
7	Flow goes forward and cells step backward: endothelial migration. Experimental and Molecular Medicine, 2022, 54, 711-719.	7.7	16
8	The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy. Nature Reviews Cardiology, 2021, 18, 565-580.	13.7	115
9	Developmental Perspectives on Arterial Fate Specification. Frontiers in Cell and Developmental Biology, 2021, 9, 691335.	3.7	6
10	Emerging roles of PLCÎ³1 in endothelial biology. Science Signaling, 2021, 14, .	3.6	13
11	Fibroblast growth factors: the keepers of endothelial normalcy. Journal of Clinical Investigation, 2021, 131, .	8.2	6
12	Role of Venous Endothelial Cells in Developmental and Pathologic Angiogenesis. Circulation, 2021, 144, 1308-1322.	1.6	66
13	Activation of Smad2/3 signaling by low fluid shear stress mediates artery inward remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	32
14	MEKK3â€“TGFÎ² crosstalk regulates inward arterial remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	17
15	FRS2Îą-dependent cell fate transition during endocardial cushion morphogenesis. Developmental Biology, 2020, 458, 88-97.	2.0	2
16	Isoform-Specific Roles of ERK1 and ERK2 in Arteriogenesis. Cells, 2020, 9, 38.	4.1	19
17	Amyloid-Î² Precursor Protein APP Down-Regulation Alters Actin Cytoskeleton-Interacting Proteins in Endothelial Cells. Cells, 2020, 9, 2506.	4.1	11
18	Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis. Frontiers in Cardiovascular Medicine, 2020, 7, 53.	2.4	72

#	Article	IF	Citations
19	Smooth Muscle Cell Reprogramming in Aortic Aneurysms. Cell Stem Cell, 2020, 26, 542-557.e11.	11.1	114
20	Chronic mTOR activation induces a degradative smooth muscle cell phenotype. Journal of Clinical Investigation, 2020, 130, 1233-1251.	8.2	59
21	Resilience, disease and the age of single cell science. Aging, 2020, 12, 2028-2029.	3.1	2
22	In silico phenotype projection of endothelial ERK1/2 signaling. Aging, 2020, 12, 10001-10003.	3.1	0
23	Endothelial TGF-Î² signalling drives vascular inflammation and atherosclerosis. Nature Metabolism, 2019, 1, 912-926.	11.9	172
24	Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium. Journal of Experimental Medicine, 2019, 216, 1874-1890.	8.5	47
25	N-terminal syndecan-2 domain selectively enhances 6-O heparan sulfate chains sulfation and promotes VEGFA165-dependent neovascularization. Nature Communications, 2019, 10, 1562.	12.8	59
26	A unifying concept in vascular health and disease. Science, 2018, 360, 270-271.	12.6	75
27	Endothelial Cell Autonomous Role of Akt1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 870-879.	2.4	34
28	The Rab-effector protein RABEP2 regulates endosomal trafficking to mediate vascular endothelial growth factor receptor-2 (VEGFR2)-dependent signaling. Journal of Biological Chemistry, 2018, 293, 4805-4817.	3.4	35
29	Reprogramming the Endocardium. Circulation Research, 2018, 122, 913-915.	4.5	1
30	Fibroblast growth factorâ€“transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis. Current Opinion in Lipidology, 2018, 29, 397-403.	2.7	18
31	Metabolic Analysis of Lymphatic Endothelial Cells. Methods in Molecular Biology, 2018, 1846, 325-334.	0.9	7
32	Endothelial Metabolic Control of Lymphangiogenesis. BioEssays, 2018, 40, e1700245.	2.5	10
33	SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis. Nature Communications, 2018, 9, 3303.	12.8	56
34	Lacteal junction zippering protects against diet-induced obesity. Science, 2018, 361, 599-603.	12.6	162
35	Recent advances in understanding lymphangiogenesis and metabolism. F1000Research, 2018, 7, 1114.	1.6	10
36	Abstract 17179: Blunted Vasoreactivity and Loss of Flow Reserve Contribute to Impaired Arteriogenesis in Diabetic Peripheral Artery Disease. Circulation, 2018, 138, .	1.6	0

#	Article	IF	Citations
37	Post-endocytic sorting of Plexin-D1 controls signal transduction and development of axonal and vascular circuits. Nature Communications, 2017, 8, 14508.	12.8	32
38	The molecular basis of endothelial cell plasticity. Nature Communications, 2017, 8, 14361.	12.8	333
39	FGF-dependent metabolic control of vascular development. Nature, 2017, 545, 224-228.	27.8	256
40	SUMOylation Negatively Regulates Angiogenesis by Targeting Endothelial NOTCH Signaling. Circulation Research, 2017, 121, 636-649.	4.5	36
41	Modulation of VEGF receptor 2 signaling by protein phosphatases. Pharmacological Research, 2017, 115, 107-123.	7.1	40
42	Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight, 2017, 2, .	5.0	16
43	Smooth muscle <scp>FGF</scp> / <scp>TGF</scp> Î² cross talk regulates atherosclerosis progression. EMBO Molecular Medicine, 2016, 8, 712-728.	6.9	61
44	The expanding role of neuropilin. Current Opinion in Hematology, 2016, 23, 260-267.	2.5	41
45	Mechanisms and regulation of endothelial VEGF receptor signalling. Nature Reviews Molecular Cell Biology, 2016, 17, 611-625.	37.0	1,034
46	Sympathetic Innervation Promotes Arterial Fate by Enhancing Endothelial ERK Activity. Circulation Research, 2016, 119, 607-620.	4.5	17
47	Fibroblast growth factor (FGF) signaling regulates transforming growth factor beta (TGFÎ²)-dependent smooth muscle cell phenotype modulation. Scientific Reports, 2016, 6, 33407.	3.3	65
48	Syndecan-4 controls lymphatic vasculature remodeling during embryonic development. Development (Cambridge), 2016, 143, 4441-4451.	2.5	33
49	When endothelial cells go rogue. EMBO Molecular Medicine, 2016, 8, 1-2.	6.9	47
50	Syndecan 4 controls lymphatic vasculature remodeling during mouse embryonic development. Journal of Cell Science, 2016, 129, e1.1-e1.1.	2.0	1
51	Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition. Current Drug Targets, 2016, 17, 1707-1713.	2.1	7
52	Myosin <scp>VI</scp> and cardiomyopathy: Left ventricular hypertrophy, fibrosis, and both cardiac and pulmonary vascular endothelial cell defects in the <scp>S</scp>nell's waltzer mouse. Cytoskeleton, 2015, 72, 373-387.	2.0	17
53	Angiogenesis versus arteriogenesis: neuropilin 1 modulation of VEGF signaling. F1000prime Reports, 2015, 7, 26.	5.9	57
54	TGFÎ²R1 Inhibition Blocks the Formation of Stenosis in Tissue-Engineered Vascular Grafts. Journal of the American College of Cardiology, 2015, 65, 512-514.	2.8	27

#	Article	IF	Citations
55	Up-regulation of Thrombospondin-2 in Akt1-null Mice Contributes to Compromised Tissue Repair Due to Abnormalities in Fibroblast Function. Journal of Biological Chemistry, 2015, 290, 409-422.	3.4	14
56	When It Is Better to Regress: Dynamics of Vascular Pruning. PLoS Biology, 2015, 13, e1002148.	5.6	30
57	State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization. Circulation Research, 2015, 116, e99-132.	4.5	113
58	Cardiomyopathy and Worsened Ischemic Heart Failure in SM22-Î± Cre-Mediated Neuropilin-1 Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1401-1412.	2.4	40
59	Molecular Controls of Arterial Morphogenesis. Circulation Research, 2015, 116, 1712-1724.	4.5	109
60	Molecular Controls of Lymphatic VEGFR3 Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 421-429.	2.4	113
61	Endothelial Cell Metabolism in Normal and Diseased Vasculature. Circulation Research, 2015, 116, 1231-1244.	4.5	462
62	Endothelial miR-17â^¼92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12812-12817.	7.1	61
63	Endothelial-to-mesenchymal transition drives atherosclerosis progression. Journal of Clinical Investigation, 2015, 125, 4514-4528.	8.2	394
64	Inter-Cellular Exchange of Cellular Components via VE-Cadherin-Dependent Trans-Endocytosis. PLoS ONE, 2014, 9, e90736.	2.5	10
65	Fibroblast growth factor receptor 1 is a key inhibitor of TGFÎ² signaling in the endothelium. Science Signaling, 2014, 7, ra90.	3.6	89
66	ELAVL1 regulates alternative splicing of eIF4E transporter to promote postnatal angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18309-18314.	7.1	54
67	Lymphatic fate specification: An ERK-controlled transcriptional program. Microvascular Research, 2014, 96, 10-15.	2.5	22
68	Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17308-17313.	7.1	133
69	Fox(y) Regulators of VEGF Receptors. Circulation Research, 2014, 115, 683-685.	4.5	1
70	Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance. Cancer Cell, 2014, 25, 350-365.	16.8	203
71	Endothelial signaling and the molecular basis of arteriovenous malformation. Cellular and Molecular Life Sciences, 2014, 71, 867-883.	5.4	30
72	Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature, 2014, 505, 97-102.	27.8	496

#	Article	IF	Citations
73	<scp>VEGF</scp> â€Bâ€induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Molecular Medicine, 2014, 6, 307-321.	6.9	127
74	A Brief Etymology of the Collateral Circulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1854-1859.	2.4	129
75	Angiopoietin-2 Secretion by Endothelial Cell Exosomes. Journal of Biological Chemistry, 2014, 289, 510-519.	3.4	79
76	Chemokine-coupled Î²2 integrinâ€“induced macrophage Rac2â€“Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis. Journal of Experimental Medicine, 2014, 211, 1957-1968.	8.5	43
77	Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12865-12870.	7.1	120
78	The docking protein FRS2Î± is a critical regulator of VEGF receptors signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5514-5519.	7.1	20
79	Flow-regulated lymphatic vasculature development and signaling. Vascular Cell, 2014, 6, 14.	0.2	9
80	Receptor Tyrosine Kinases Endocytosis in Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1831-1837.	2.4	31
81	PTP1b Is a Physiologic Regulator of Vascular Endothelial Growth Factor Signaling in Endothelial Cells. Circulation, 2014, 130, 902-909.	1.6	90
82	Vasa Vasorum in Normal and Diseased Arteries. Circulation, 2014, 129, 2557-2566.	1.6	154
83	Netrin-1 controls sympathetic arterial innervation. Journal of Clinical Investigation, 2014, 124, 3230-3240.	8.2	74
84	Chemokine-coupled Î²₂integrinâ€“induced macrophage Rac2â€“Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis. Journal of Cell Biology, 2014, 206, 2066OIA157.	5.2	0
85	Syndecan-4 signaling at a glance. Journal of Cell Science, 2013, 126, 3799-804.	2.0	171
86	Endothelial Cellâ€“Dependent Regulation of Arteriogenesis. Circulation Research, 2013, 113, 1076-1086.	4.5	58
87	Syndecan 4 regulation of PDK1-dependent Akt activation. Cellular Signalling, 2013, 25, 101-105.	3.6	16
88	Dll4-Notch signaling determines the formation of native arterial collateral networks and arterial function in mouse ischemia models. Development (Cambridge), 2013, 140, 1720-1729.	2.5	60
89	Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell, 2013, 23, 477-488.	16.8	138
90	The Neuropilin 1 Cytoplasmic Domain Is Required for VEGF-A-Dependent Arteriogenesis. Developmental Cell, 2013, 25, 156-168.	7.0	184

#	Article	IF	Citations
91	Lymphatics Are in My Veins. Science, 2013, 341, 622-624.	12.6	15
92	Effects of Cell Grafting on Coronary Remodeling After Myocardial Infarction. Journal of the American Heart Association, 2013, 2, e000202.	3.7	14
93	Need glucose to sprout: local metabolic control of angiogenesis. EMBO Molecular Medicine, 2013, 5, 1459-1461.	6.9	11
94	The Syndecan-4/Protein Kinase CÎ± Pathway Mediates Prostaglandin E2-induced Extracellular Regulated Kinase (ERK) Activation in Endothelial Cells and Angiogenesis in Vivo. Journal of Biological Chemistry, 2013, 288, 12712-12721.	3.4	37
95	VEGFR2 trafficking: Speed doesnâ€™t kill. Cell Cycle, 2013, 12, 2163-2164.	2.6	14
96	Lymphatic fate determination: Playing RAF with ERK. Cell Cycle, 2013, 12, 1157-1158.	2.6	10
97	Endothelial RAF1/ERK activation regulates arterial morphogenesis. Blood, 2013, 121, 3988-3996.	1.4	57
98	Endothelial ERK signaling controls lymphatic fate specification. Journal of Clinical Investigation, 2013, 123, 1202-1215.	8.2	114
99	NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. Journal of Clinical Investigation, 2013, 123, 1718-1731.	8.2	72
100	Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. Journal of Clinical Investigation, 2013, 123, 5082-5097.	8.2	52
101	Endothelial Nuclear Factor-ÎºBâ€“Dependent Regulation of Arteriogenesis and Branching. Circulation, 2012, 126, 2589-2600.	1.6	57
102	Lymphatics thrive on stress: mechanical force in lymphatic development. EMBO Journal, 2012, 31, 781-782.	7.8	5
103	Syndecan 4 Regulates FGFR1 Signaling in Endothelial Cells by Directing Macropinocytosis. Science Signaling, 2012, 5, ra36.	3.6	63
104	Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development (Cambridge), 2012, 139, 4449-4460.	2.5	96
105	Profilin phosphorylation as a VEGFR effector in angiogenesis. Nature Cell Biology, 2012, 14, 985-987.	10.3	9
106	Frs2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor Î²-mediated regulation of vascular smooth muscle marker gene expression.. Journal of Biological Chemistry, 2012, 287, 1609.	3.4	1
107	Fibroblast Growth Factor-2 Is Required for Vasa Vasorum Plexus Stability in Hypercholesterolemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2644-2651.	2.4	23
108	FGF Regulates TGF-Î² Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression. Cell Reports, 2012, 2, 1684-1696.	6.4	265

#	Article	IF	Citations
109	Vascular adaptation to a dysfunctional endothelium as a consequence of Shb deficiency. Angiogenesis, 2012, 15, 469-480.	7.2	17
110	ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway. Developmental Cell, 2012, 22, 489-500.	7.0	322
111	An Inside View: VEGF Receptor Trafficking and Signaling. Physiology, 2012, 27, 213-222.	3.1	118
112	â€œOn-Targetâ€•Cardiac Effects of Anticancer Drugs. Journal of the American College of Cardiology, 2012, 60, 626-627.	2.8	12
113	Heterogeneity among RIPâ€Tag2 insulinomas allows vascular endothelial growth factorâ€A independent tumor expansion as revealed by studies in Shb mutant mice: Implications for tumor angiogenesis. Molecular Oncology, 2012, 6, 333-346.	4.6	17
114	Fibroblast Growth Factor Signaling Potentiates VE-Cadherin Stability at Adherens Junctions by Regulating SHP2. PLoS ONE, 2012, 7, e37600.	2.5	47
115	VEGF signaling inside vascular endothelial cells and beyond. Current Opinion in Cell Biology, 2012, 24, 188-193.	5.4	221
116	Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H162-H172.	3.2	70
117	Development and Application of a Multimodal Contrast Agent for SPECT/CT Hybrid Imaging. Bioconjugate Chemistry, 2011, 22, 1784-1792.	3.6	53
118	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature, 2011, 479, 122-126.	27.8	265
119	Challenging the Surgical Rodent Hindlimb Ischemia Model with the Miniinterventional Technique. Journal of Vascular and Interventional Radiology, 2011, 22, 1437-1446.	0.5	11
120	Endothelial-Derived Angiocrine Signals Induce and Sustain Regenerative Lung Alveolarization. Cell, 2011, 147, 539-553.	28.9	436
121	FGF-dependent regulation of VEGF receptor 2 expression in mice. Journal of Clinical Investigation, 2011, 121, 2668-2678.	8.2	156
122	Antiangiogenic Activity of rPAI-1 ₂₃ Promotes Vasa Vasorum Regression in Hypercholesterolemic Mice Through a Plasmin-Dependent Mechanism. Circulation Research, 2011, 108, 1419-1428.	4.5	22
123	FGFâ€VEGF crosstalk regulating vascular integrity and angiogenesis. FASEB Journal, 2011, 25, 1091.5.	0.5	1
124	Role of synectin in lymphatic development in zebrafish and frogs. Blood, 2010, 116, 3356-3366.	1.4	36
125	Embryonic coronary vasculogenesis and angiogenesis are regulated by interactions between multiple FGFs and VEGF and are influenced by mesenchymal stem cells. Developmental Dynamics, 2010, 239, 3182-3191.	1.8	25
126	Micro computed tomography for vascular exploration. Journal of Angiogenesis Research, 2010, 2, 7.	2.9	112

#	Article	IF	Citations
127	Cell Communications in the Heart. Circulation, 2010, 122, 928-937.	1.6	243
128	Auxiliary and Autonomous Proteoglycan Signaling Networks. Methods in Enzymology, 2010, 480, 3-31.	1.0	17
129	VEGF Receptor 2 Endocytic Trafficking Regulates Arterial Morphogenesis. Developmental Cell, 2010, 18, 713-724.	7.0	213
130	ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. Journal of Clinical Investigation, 2010, 120, 1217-1228.	8.2	136
131	FGF regulation of myocardial integrity and angiogenesis. FASEB Journal, 2010, 24, 180.1.	0.5	0
132	Agingâ€induced collateral impairment: role of arterial rarefaction, decreased eNOS expression/signaling, and increased susceptibility of endothelial cells to apoptosis. FASEB Journal, 2010, 24, 294.3.	0.5	0
133	Targeting GIPC/Synectin in Pancreatic Cancer Inhibits Tumor Growth. Clinical Cancer Research, 2009, 15, 4095-4103.	7.0	40
134	FRS2 via Fibroblast Growth Factor Receptor 1 Is Required for Platelet-derived Growth Factor Receptor Î²-mediated Regulation of Vascular Smooth Muscle Marker Gene Expression. Journal of Biological Chemistry, 2009, 284, 15980-15992.	3.4	43
135	Suppression of RhoG activity is mediated by a syndecan 4â€“synectinâ€“RhoGDI1 complex and is reversed by PKCÎ± in a Rac1 activation pathway. Journal of Cell Biology, 2009, 186, 75-83.	5.2	82
136	VEGF and Restenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 439-440.	2.4	14
137	Branching Morphogenesis. Circulation Research, 2009, 104, e21.	4.5	19
138	Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. Journal of Lipid Research, 2009, 50, 641-650.	4.2	44
139	The Antiangiogenic Activity of rPAI-1 ₂₃ Inhibits Vasa Vasorum and Growth of Atherosclerotic Plaque. Circulation Research, 2009, 104, 337-345.	4.5	70
140	Abnormalities in the Regulators of Angiogenesis in Patients with Scleroderma. Journal of Rheumatology, 2009, 36, 576-582.	2.0	92
141	Diabetic Monocyte and Vascular Endothelial Growth Factor Signaling Impairment. Circulation, 2009, 120, 104-105.	1.6	63
142	Endothelium as master regulator of organ development and growth. Vascular Pharmacology, 2009, 50, 1-7.	2.1	38
143	Synectinâ€dependent regulation of arterial maturation. Developmental Dynamics, 2009, 238, 604-610.	1.8	9
144	Regulation of vascular integrity. Journal of Molecular Medicine, 2009, 87, 571-582.	3.9	89

#	Article	IF	Citations
145	Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. International Journal of Biochemistry and Cell Biology, 2009, 41, 800-810.	2.8	72
146	Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization. Cell, 2009, 136, 839-851.	28.9	727
147	The FGF system has a key role in regulating vascular integrity. Journal of Clinical Investigation, 2009, 119, 2113-2113.	8.2	1
148	Reduced-Dose Fibrinolytic Acceleration of ST-Segment Elevation Myocardial Infarction Treatment Coupled With Urgent Percutaneous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention Alone. JACC: Cardiovascular Interventions, 2008, 1, 504-510.	2.9	36
149	Endothelium-Driven Myocardial Growth or Nitric Oxide at the Crossroads. Trends in Cardiovascular Medicine, 2008, 18, 299-305.	4.9	23
150	Stem cell therapies in cardiovascular disease. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 73-78.	0.5	3
151	Syndecan-4 Regulates Subcellular Localization of mTOR Complex2 and Akt Activation in a PKCÎ±-Dependent Manner in Endothelial Cells. Molecular Cell, 2008, 32, 140-149.	9.7	103
152	Molecular Basis for Proline- and Arginine-Rich Peptide Inhibition of Proteasome. Journal of Molecular Biology, 2008, 384, 219-227.	4.2	55
153	Vascular Disease in Scleroderma: Angiogenesis and Vascular Repair. Rheumatic Disease Clinics of North America, 2008, 34, 73-79.	1.9	33
154	Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovascular Research, 2008, 78, 223-231.	3.8	82
155	Neuropilin-1-VEGFR-2 Complexing Requires the PDZ-binding Domain of Neuropilin-1. Journal of Biological Chemistry, 2008, 283, 25110-25114.	3.4	117
156	Branching Morphogenesis. Circulation Research, 2008, 103, 784-795.	4.5	144
157	Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia. Circulation, 2008, 118, 58-65.	1.6	281
158	Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation. Circulation Research, 2008, 102, 986-993.	4.5	112
159	Vascular Endothelial Growth Factor and Semaphorin Induce Neuropilin-1 Endocytosis via Separate Pathways. Circulation Research, 2008, 103, e71-9.	4.5	102
160	Chapter 14 Assessment of Arteriogenesis. Methods in Enzymology, 2008, 445, 331-342.	1.0	6
161	Fibroblast growth factor regulation of neovascularization. Current Opinion in Hematology, 2008, 15, 215-220.	2.5	259
162	The FGF system has a key role in regulating vascular integrity. Journal of Clinical Investigation, 2008, 118, 3355-3366.	8.2	257

#	Article	IF	Citations
163	Journeys in Coronary Angiogenesis. , 2008, , 561-573.		0
164	FGF mediates maintenance of vascular integrity in a Csk dependent manner. FASEB Journal, 2008, 22, 329.5.	0.5	0
165	Arterial branching morphogenesis. FASEB Journal, 2008, 22, 520.1.	0.5	0
166	Silky, Sticky Chimeras-Designer VEGFs Display Their Wares. Circulation Research, 2007, 100, 1402-1404.	4.5	3
167	Syndecans. , 2007, , 396-402.		0
168	Fibroblast Growth Factors. , 2007, , 291-303.		0
169	Introductory Essay: Endothelial Cell Coupling. , 2007, , 627-631.		0
170	Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 3448-3458.	6.7	61
171	Synectin/syndecan-4 regulate coronary arteriolar growth during development. Developmental Dynamics, 2007, 236, 2004-2010.	1.8	23
172	Progress and Prospects: Gene Therapy Clinical Trials (Part 1). Gene Therapy, 2007, 14, 1439-1447.	4.5	106
173	The extracellular matrix and blood vessel formation: not just a scaffold. Journal of Cellular and Molecular Medicine, 2007, 11, 176-205.	3.6	188
174	Current concepts in normal and defective angiogenesis: Implications for systemic sclerosis. Current Rheumatology Reports, 2007, 9, 173-179.	4.7	21
175	Protection Against Myocardial Ischemiaâ€“Reperfusion Injury by the Angiogenic Masterswitch Protein PR 39 Gene Therapy: The Roles of HIF1Î± Stabilization and FGFR1 Signaling. Antioxidants and Redox Signaling, 2007, 9, 437-445.	5.4	29
176	Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. Journal of Clinical Investigation, 2007, 117, 3188-3197.	8.2	129
177	THE ANTIâ€ANGIOGENIC ACTIVITY OF rPAIâ€1 23 INHIBITS ANGIOGENIC VASA VASORUM AND ATHERSCLEROTIC PLAQUE GROWTH. FASEB Journal, 2007, 21, A16.	0.5	0
178	Overview of Angiogenesis. , 2007, , 225-232.		0
179	Endothelial Activation and Neointimal Hyperplasia: A Double-Edged Sword. , 2007, , 75-84.		0
180	Selective Regulation of Arterial Branching Morphogenesis by Synectin. Developmental Cell, 2006, 10, 783-795.	7.0	125

#	Article	IF	Citations
181	Synectin-dependent gene expression in endothelial cells. Physiological Genomics, 2006, 27, 380-390.	2.3	13
182	Plasminogen and plasmin activity in patients with coronary artery disease. Journal of Thrombosis and Haemostasis, 2006, 4, 1288-1295.	3.8	22
183	Progress and prospects: Cell based regenerative therapy for cardiovascular disease. Gene Therapy, 2006, 13, 659-671.	4.5	13
184	Humoral and Cellular Factors Responsible for Coronary Collateral Formation. American Journal of Cardiology, 2006, 98, 1194-1197.	1.6	46
185	Comparison of transendocardial and retrograde coronary venous intramyocardial catheter delivery systems in healthy and infarcted pigs. Catheterization and Cardiovascular Interventions, 2006, 68, 416-423.	1.7	19
186	Arteriogenesis: Noninvasive Quantification with Multiâ€“Detector Row CT Angiography and Three-dimensional Volume Rendering in Rodents. Radiology, 2006, 240, 698-707.	7.3	25
187	Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R494-R500.	1.8	43
188	High-Resolution Quantitative Computed Tomography Demonstrating Selective Enhancement of Medium-Size Collaterals by Placental Growth Factor-1 in the Mouse Ischemic Hindlimb. Circulation, 2006, 113, 2445-2453.	1.6	33
189	Syndecan-4 Clustering Induces Cell Migration in a PDZ-Dependent Manner. Circulation Research, 2006, 98, 1398-1404.	4.5	68
190	Postmarket Surveillance for Drug-Eluting Coronary Stents. Circulation, 2006, 113, 891-897.	1.6	18
191	Transcriptional Profiling in Coronary Artery Disease. Circulation, 2006, 114, 1811-1820.	1.6	51
192	The Anti-angiogenic Activity of rPAI-123 Inhibits Fibroblast Growth Factor-2 Functions. Journal of Biological Chemistry, 2006, 281, 33336-33344.	3.4	14
193	Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2692-H2697.	3.2	9
194	Syndecanâ€4 plays a key role in the phosphorylation of protein kinase B / Akt. FASEB Journal, 2006, 20, A1080.	0.5	0
195	Live 3D echo guidance of catheter-based endomyocardial injection. Catheterization and Cardiovascular Interventions, 2005, 65, 340-345.	1.7	23
196	Angiogenesis in the human heart: Gene and cell therapy. Angiogenesis, 2005, 8, 241-251.	7.2	56
197	PKCÎ± Activates eNOS and Increases Arterial Blood Flow In Vivo. Circulation Research, 2005, 97, 482-487.	4.5	85
198	Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovascular Research, 2005, 65, 649-655.	3.8	79

#	Article	IF	Citations
199	Role of Angiogenesis in Cardiovascular Disease. Circulation, 2005, 112, 1813-1824.	1.6	413
200	Syndecans. Circulation Research, 2005, 96, 488-500.	4.5	397
201	Delayed Arteriogenesis in Hypercholesterolemic Mice. Circulation, 2005, 112, 2501-2509.	1.6	100
202	Calling on Reserves. Circulation, 2005, 112, 3033-3035.	1.6	8
203	Angiogenesis. Circulation, 2005, 111, 1556-1566.	1.6	400
204	PR39 Inhibits Apoptosis in Hypoxic Endothelial Cells. Circulation, 2004, 109, 1660-1667.	1.6	62
205	Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia. Circulation, 2004, 110, 2436-2443.	1.6	172
206	Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vascular Medicine, 2004, 9, 193-198.	1.5	34
207	Post-Market Approval Surveillance. Circulation, 2004, 109, 3073-3077.	1.6	35
208	Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. Journal of Cell Science, 2004, 117, 3189-3199.	2.0	129
209	Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase CÎ± in endothelial cells. Cellular Signalling, 2004, 16, 951-957.	3.6	104
210	Integrative signaling in angiogenesis. Molecular and Cellular Biochemistry, 2004, 264, 99-102.	3.1	56
211	Medical Device Development. Circulation, 2004, 109, 3068-3072.	1.6	142
212	Characterization of synectin expression and promoter activity. Gene, 2004, 342, 29-34.	2.2	6
213	Re-evaluating therapeutic neovascularization. Journal of Molecular and Cellular Cardiology, 2004, 36, 25-32.	1.9	56
214	MRI of angiogenesis. , 2004, , 471-499.		0
215	Spatial Heterogeneity in VEGF-induced Vasodilation: VEGF Dilates Microvessels but Not Epicardial and Systemic Arteries and Veins. Annals of Vascular Surgery, 2003, 17, 245-252.	0.9	41
216	Insights from Angiogenesis Trials Using Fibroblast Growth Factor for Advanced Arteriosclerotic Disease. Trends in Cardiovascular Medicine, 2003, 13, 116-122.	4.9	88

#	Article	IF	Citations
217	Evolving revascularization approaches for myocardial ischemia. American Journal of Cardiology, 2003, 92, 9-17.	1.6	120
218	Therapeutic angiogenesis in cardiovascular disease. Nature Reviews Drug Discovery, 2003, 2, 863-872.	46.4	287
219	Proline- and Arginine-Rich Peptides Constitute a Novel Class of Allosteric Inhibitors of Proteasome Activityâ€. Biochemistry, 2003, 42, 8663-8670.	2.5	112
220	Endothelial progenitor cells: Precursors for angiogenesis. Seminars in Thoracic and Cardiovascular Surgery, 2003, 15, 250-258.	0.6	14
221	Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7283-7288.	7.1	132
222	Arteriogenesis: Lessons Learned from Clinical Trials. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 217-223.	1.7	19
223	Copper chelation represses the vascular response to injury. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6700-6705.	7.1	113
224	Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H352-H358.	3.2	88
225	Translational Physiology: Porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. Journal of Applied Physiology, 2003, 94, 1689-1701.	2.5	120
226	Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H2078-H2082.	3.2	52
227	Arteriogenesis: Lessons Learned from Clinical Trials. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 217-223.	1.7	9
228	Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein Eâ€“Deficient Mice. Circulation Research, 2002, 90, 270-276.	4.5	461
229	Clustering Induces Redistribution of Syndecan-4 Core Protein into Raft Membrane Domains. Journal of Biological Chemistry, 2002, 277, 19946-19951.	3.4	96
230	Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2. Circulation, 2002, 105, 788-793.	1.6	621
231	Fibroblast growth factorâ€“specific modulation of cellular response by syndecan-4. Journal of Cell Biology, 2002, 157, 715-725.	5.2	160
232	Protein Kinase C (PKC) Î´ Regulates PKCÎ± Activity in a Syndecan-4-dependent Manner. Journal of Biological Chemistry, 2002, 277, 20367-20371.	3.4	74
233	Modulation of Microvascular Signaling by Heparan Sulfate Matrix: Studies in Syndecan-4 Transgenic Mice. Microvascular Research, 2002, 64, 38-46.	2.5	21
234	Magnetic resonance imaging demonstrates improved regional systolic wall motion and thickening and myocardial perfusion of myocardial territories treated by laser myocardial revascularization. Journal of the American College of Cardiology, 2002, 39, 1-8.	2.8	35

#	Article	IF	Citations
235	Medical Imaging Techniques in the Evaluation of Strategies for Therapeutic Angiogenesis. Current Pharmaceutical Design, 2002, 8, 1467-1496.	1.9	41
236	Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 28-34.	0.8	145
237	The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clinical Cardiology, 2002, 25, 271-278.	1.8	7
238	Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1Î±-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. Journal of Cell Science, 2002, 115, 1951-1959.	2.0	69
239	Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. Journal of Cell Science, 2002, 115, 1951-9.	2.0	57
240	Efficacy of intracoronary or intravenous VEGF165in a pig model of chronic myocardial ischemia. Journal of the American College of Cardiology, 2001, 37, 616-623.	2.8	96
241	Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. American Heart Journal, 2001, 142, 872-880.	2.7	196
242	Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi?. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H1923-H1927.	3.2	25
243	PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IÎºBÎ± degradation. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H2612-H2618.	3.2	98
244	Serial Motion Assessment by Reference Tracking (SMART): Application to Detection of Local Functional Impact of Chronic Myocardial Ischemia. Journal of Computer Assisted Tomography, 2001, 25, 558-562.	0.9	5
245	Pharmacokinetics and Pharmacodynamics of Recombinant FGFâ€2 in a Phase I Trial in Coronary Artery Disease. Journal of Clinical Pharmacology, 2001, 41, 378-385.	2.0	44
246	Serotonin-induced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition. Basic Research in Cardiology, 2001, 96, 59-67.	5.9	35
247	Intramyocardial delivery of FGF2 in combination with radio frequency transmyocardial revascularization. Catheterization and Cardiovascular Interventions, 2001, 53, 429-434.	1.7	6
248	An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). American Journal of Cardiology, 2001, 88, 482-487.	1.6	63
249	Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. Journal of Thoracic and Cardiovascular Surgery, 2001, 121, 735-742.	0.8	34
250	Gene therapy versus protein-based therapy: a matter of pharmacokinetics. Drug Discovery Today, 2001, 6, 769-770.	6.4	9
251	Syndecan-4-mediated signalling. Cellular Signalling, 2001, 13, 855-862.	3.6	132
252	Therapeutic angiogenesis in cardiology using protein formulations. Cardiovascular Research, 2001, 49, 522-531.	3.8	164

#	Article	IF	Citations
253	Gene Transfer for Angiogenesis in Coronary Artery Disease. Annual Review of Medicine, 2001, 52, 485-502.	12.2	48
254	Coronary Artery Disease: Vascular Endothelial Growth Factor and Fibroblast Growth Factor. Current Interventional Cardiology Reports, 2001, 3, 185-191.	0.4	2
255	Synectin, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. Journal of Cellular Physiology, 2000, 184, 373-379.	4.1	164
256	PR39, a peptide regulator of angiogenesis. Nature Medicine, 2000, 6, 49-55.	30.7	359
257	Molecular multitasking: statins lead to more arteries, less plaque. Nature Medicine, 2000, 6, 965-966.	30.7	37
258	Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. Circulation, 2000, 102, E73-86.	1.6	390
259	Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H260-H268.	3.2	34
260	Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion. Circulation, 2000, 101, 118-121.	1.6	280
261	Coronary Angiogenesis: Detection in Vivo with MR Imaging Sensitive to Collateral Neocirculationâ€"Preliminary Study in Pigs. Radiology, 2000, 214, 801-807.	7.3	49
262	Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease. Circulation, 2000, 102, 1605-1610.	1.6	156
263	Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2. Journal of Biological Chemistry, 2000, 275, 32167-32173.	3.4	217
264	Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Annals of Thoracic Surgery, 2000, 70, 2113-2118.	1.3	77
265	Therapeutic Angiogenesis. BioDrugs, 2000, 14, 13-20.	4.6	6
266	Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. Journal of the American College of Cardiology, 2000, 36, 2132-2139.	2.8	216
267	Inhibition of ubiquitin-proteasome pathwayâ€"mediated ÎºBÎ± degradation by a naturally occurring antibacterial peptide. Journal of Clinical Investigation, 2000, 106, 439-448.	8.2	147
268	Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. Journal of Pharmacology and Experimental Therapeutics, 2000, 292, 795-802.	2.5	93
269	Anti-angiogenic cues from vascular basement membrane collagen. Cancer Research, 2000, 60, 2520-6.	0.9	324
270	Angiogenesis: Therapeutic Applications--Second Annual Meeting. 13-14 December 1999, Washington DC, USA. IDrugs: the Investigational Drugs Journal, 2000, 3, 287-8.	0.7	0

#	Article	IF	Citations
271	Attenuation of Endothelium-Dependent Dilation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass Is Prevented by Monoclonal Antibody to Complement C5a. Anesthesia and Analgesia, 1999, 89, 42-48.	2.2	12
272	The Role of Syndecan Cytoplasmic Domain in Basic Fibroblast Growth Factor-dependent Signal Transduction. Journal of Biological Chemistry, 1999, 274, 24417-24424.	3.4	113
273	Myocyte-dependent Regulation of Endothelial Cell Syndecan-4 Expression. Journal of Biological Chemistry, 1999, 274, 14786-14790.	3.4	60
274	Scaling features of noncoding DNA. Physica A: Statistical Mechanics and Its Applications, 1999, 273, 1-18.	2.6	104
275	Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery. Clinical Cardiology, 1999, 22, 6-9.	1.8	29
276	Subxyphoid access of the normal pericardium: A novel drug delivery technique. Catheterization and Cardiovascular Interventions, 1999, 47, 109-111.	1.7	40
277	Effect of sialyl Lewisx oligosaccharide on myocardial and cerebral injury in the pig. Annals of Thoracic Surgery, 1999, 67, 112-119.	1.3	8
278	Angiogenesis in Cardiovascular Disease. Drugs, 1999, 58, 391-396.	10.9	31
279	Phosphatidylinositol-4,5-bisphosphate Mediates the Interaction of Syndecan-4 with Protein Kinase Câ€. Biochemistry, 1999, 38, 15871-15877.	2.5	85
280	Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery. Circulation, 1999, 100, 1865-1871.	1.6	398
281	Angiographic methods to assess human coronary angiogenesis. American Heart Journal, 1999, 137, 169-179.	2.7	63
282	Cloning, Expression, andin VitroActivity of Human Endostatin. Biochemical and Biophysical Research Communications, 1999, 258, 345-352.	2.1	181
283	Attenuation of Endothelium-Dependent Dilation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass Is Prevented by Monoclonal Antibody to Complement C5a. Anesthesia and Analgesia, 1999, 89, 42-48.	2.2	23
284	Subxyphoid access of the normal pericardium: A novel drug delivery technique. Catheterization and Cardiovascular Interventions, 1999, 47, 109-111.	1.7	1
285	Chronic myocardial ischemia: Contemporary management strategies. Drugs of Today, 1999, 35, 667.	2.4	1
286	Vascular Antisense Therapy Directed Against c-myc, c-myb and PCNA. Perspectives in Antisense Science, 1999, , 71-98.	0.2	0
287	Myocardial Ischemia and Growth Factor Therapy. , 1999, , 125-145.		1
288	Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Research, 1999, 59, 189-97.	0.9	196

#	Article	IF	Citations
289	Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metabolism and Disposition, 1999, 27, 821-6.	3.3	85
290	Novel vascularization strategies. IDrugs: the Investigational Drugs Journal, 1999, 2, 396-7.	0.7	0
291	Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 1022-1028.	0.8	34
292	Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 1060-1068.	0.8	59
293	Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results. Annals of Thoracic Surgery, 1998, 65, 1540-1544.	1.3	213
294	Comparison of VEGF Delivery Techniques on Collateral-Dependent Microvascular Reactivity. Microvascular Research, 1998, 55, 175-178.	2.5	22
295	Myb-dependent Regulation of Thrombospondin 2 Expression. Journal of Biological Chemistry, 1998, 273, 21423-21429.	3.4	26
296	Regulation of Syndecan-4 Phosphorylation in Vivo. Journal of Biological Chemistry, 1998, 273, 10914-10918.	3.4	93
297	Phosphorylation of the Cytoplasmic Tail of Syndecan-4 Regulates Activation of Protein Kinase CÎ±. Journal of Biological Chemistry, 1998, 273, 25548-25551.	3.4	112
298	VEGF administration in chronic myocardial ischemia in pigs. Cardiovascular Research, 1998, 40, 272-281.	3.8	172
299	Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H930-H936.	3.2	30
300	Effects of coronary artery disease on expression and microvascular response to VEGF. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1411-H1418.	3.2	21
301	Enhancement of Migration by Protein Kinase CÎ± and Inhibition of Proliferation and Cell Cycle Progression by Protein Kinase CÎ´ in Capillary Endothelial Cells. Journal of Biological Chemistry, 1997, 272, 7390-7397.	3.4	117
302	Extent of myocardial collateralization: Determination with three-dimensional elastic-subtraction spiral CT. Academic Radiology, 1997, 4, 680-686.	2.5	12
303	Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1317-H1323.	3.2	37
304	Regulation of vascular smooth muscle cell proliferation by plasma membrane Ca(2+)-ATPase. American Journal of Physiology - Cell Physiology, 1997, 272, C1947-C1959.	4.6	57
305	Angiogenesis in ischemic heart disease. Nature Medicine, 1997, 3, 158-164.	30.7	303
306	c-Myb function in fibroblasts. , 1997, 173, 319-326.		19

#	Article	IF	Citations
307	Endogenous Expression Modification: Antisense Approaches. Developments in Cardiovascular Medicine, 1997, , 143-175.	0.1	1
308	Antisense Oligonucleotide Inhibition of PDGFR-Î² Receptor Subunit Expression Directs Suppression of Intimal Thickening. Circulation, 1997, 95, 669-676.	1.6	116
309	c-Mybâ€“Dependent Cell Cycle Progression and Ca 2+ Storage in Cultured Vascular Smooth Muscle Cells. Circulation Research, 1997, 80, 617-626.	4.5	32
310	Macrophage-Dependent Regulation of Syndecan Gene Expression. Circulation Research, 1997, 81, 785-796.	4.5	83
311	Stretch-induced VEGF expression in the heart.. Journal of Clinical Investigation, 1997, 100, 18-24.	8.2	162
312	Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. Journal of Pharmacology and Experimental Therapeutics, 1997, 282, 385-90.	2.5	69
313	Perivascular delivery of prolonged half-life aFGF via EVAC results in angiographic collateral development, improvement in coronary flow and function in chronic myocardial ischemia. Journal of the American College of Cardiology, 1996, 27, 30.	2.8	3
314	Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery, 1996, 120, 182-188.	1.9	81
315	Local Extravascular Growth Factor Delivery in Myocardial Ischemia. Drug Delivery, 1996, 3, 143-147.	5.7	5
316	VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 270, H1803-H1811.	3.2	155
317	Vascular endothelial growth factor administration in chronic myocardial ischemia. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 270, H1791-H1802.	3.2	104
318	Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 271, H713-H720.	3.2	51
319	Direct Vasomotor Effects of Isoflurane in Subepicardial Resistance Vessels from Collateral-dependent and Normal Coronary Circulation of Pigs. Anesthesiology, 1996, 85, 584-591..	2.5	13
320	Antisense Approach to Restenosis. Japanese Circulation Journal, 1996, 60, 1-9.	1.0	2
321	Therapeutic manipulation of cell cycle in smooth muscle cells: Implications for restenosis. Translational Research, 1996, 128, 361-366.	2.3	4
322	â€¦and surreal antisense?. Nature Medicine, 1996, 2, 131-132.	30.7	2
323	Food for starving hearts. Nature Medicine, 1996, 2, 519-520.	30.7	26
324	Pericardial effusion in patients with cancer: outcome with contemporary management strategies.. Heart, 1996, 75, 67-71.	2.9	102

#	Article	IF	Citations
325	Statistical and Linguistic Features of DNA Sequences. , 1996, , 219-234.		0
326	Mantegnaet al.Reply:. Physical Review Letters, 1996, 76, 1979-1981.	7.8	21
327	c-Myb in Smooth Muscle Cells. , 1996, 1, 121-142.		0
328	Local perivascular administration of basic fibroblast growth factor: drug delivery and toxicological evaluation. Drug Metabolism and Disposition, 1996, 24, 922-4.	3.3	12
329	Magnetic resonance mapping demonstrates benefits of VEGFâ€“induced myocardial angiogenesis. Nature Medicine, 1995, 1, 1085-1089.	30.7	321
330	Statistical properties of DNA sequences. Physica A: Statistical Mechanics and Its Applications, 1995, 221, 180-192.	2.6	124
331	c-myb affects intracellular calcium handling in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 1995, 268, C856-C868.	4.6	47
332	Systematic analysis of coding and noncoding DNA sequences using methods of statistical linguistics. Physical Review E, 1995, 52, 2939-2950.	2.1	101
333	Long-range correlation properties of coding and noncoding DNA sequences: GenBank analysis. Physical Review E, 1995, 51, 5084-5091.	2.1	526
334	STATISTICAL AND LINGUISTIC FEATURES OF DNA SEQUENCES. Fractals, 1995, 03, 269-284.	3.7	30
335	Î²-Adrenergic Modulation of the Collateral-Dependent Coronary Microcirculation. Journal of Surgical Research, 1995, 59, 185-190.	1.6	20
336	Fractals in biology and medicine. Chaos, Solitons and Fractals, 1995, 6, 171-201.	5.1	111
337	c- myc in Vasculoproliferative Disease. Circulation Research, 1995, 76, 176-182.	4.5	90
338	Fuzzy logic, sharp results. Journal of Nuclear Medicine, 1995, 36, 1415-6.	5.0	2
339	Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation. American Journal of Physiology - Heart and Circulatory Physiology, 1994, 267, H1303-H1311.	3.2	29
340	Linguistic Features of Noncoding DNA Sequences. Physical Review Letters, 1994, 73, 3169-3172.	7.8	251
341	The impact of clinical data on interpretation of thallium scintigrams. Journal of Nuclear Cardiology, 1994, 1, 365-371.	2.1	15
342	Statistical and linguistic features of noncoding DNA: A heterogeneous Â«Complex systemÂ». Nuovo Cimento Della Societa Italiana Di Fisica D - Condensed Matter, Atomic, Molecular and Chemical Physics, Biophysics, 1994, 16, 1339-1356.	0.4	10

#	Article	IF	Citations
343	Non-equilibrium dynamics as an indispensable characteristic of a healthy biological system. Integrative Psychological and Behavioral Science, 1994, 29, 283-293.	0.3	69
344	Statistical mechanics in biology: how ubiquitous are long-range correlations?. Physica A: Statistical Mechanics and Its Applications, 1994, 205, 214-253.	2.6	153
345	Fractal Landscapes in Physiology & Medicine: Long-Range Correlations in DNA Sequences and Heart Rate Intervals. , 1994, , 55-65.		4
346	Correlation approach to identify coding regions in DNA sequences. Biophysical Journal, 1994, 67, 64-70.	0.5	174
347	Mosaic organization of DNA nucleotides. Physical Review E, 1994, 49, 1685-1689.	2.1	3,996
348	Fractals in biology and medicine. , 1994, , 147-178.		9
349	Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model.. Journal of Clinical Investigation, 1994, 93, 2351-2356.	8.2	111
350	Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts.. Journal of Clinical Investigation, 1994, 94, 623-630.	8.2	282
351	Long-range power-law correlations in condensed matter physics and biophysics. Physica A: Statistical Mechanics and Its Applications, 1993, 200, 4-24.	2.6	65
352	Finite-size effects on long-range correlations: Implications for analyzing DNA sequences. Physical Review E, 1993, 47, 3730-3733.	2.1	247
353	Fractal landscapes and molecular evolution: modeling the myosin heavy chain gene family. Biophysical Journal, 1993, 65, 2673-2679.	0.5	141
354	FRACTAL LANDSCAPES IN BIOLOGICAL SYSTEMS. Fractals, 1993, 01, 283-301.	3.7	40
355	Relation between Activated Smooth-Muscle Cells in Coronary-Artery Lesions and Restenosis after Atherectomy. New England Journal of Medicine, 1993, 328, 608-613.	27.0	121
356	Long-range fractal correlations in DNA. Physical Review Letters, 1993, 71, 1776-1776.	7.8	53
357	Generalized LÃ©vy-walk model for DNA nucleotide sequences. Physical Review E, 1993, 47, 4514-4523.	2.1	142
358	The proto-oncogene c-myb mediates an intracellular calcium rise during the late G1 phase of the cell cycle.. Journal of Biological Chemistry, 1993, 268, 627-632.	3.4	34
359	The proto-oncogene c-myb mediates an intracellular calcium rise during the late G1 phase of the cell cycle. Journal of Biological Chemistry, 1993, 268, 627-32.	3.4	23
360	Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro.. Circulation Research, 1992, 70, 835-843.	4.5	175

#	Article	IF	Citations
361	Evidence implicating nonmuscle myosin in restenosis. Use of in situ hybridization to analyze human vascular lesions obtained by directional atherectomy.. Circulation, 1992, 85, 543-553.	1.6	67
362	Long-range correlations in nucleotide sequences. Nature, 1992, 356, 168-170.	27.8	1,297
363	Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature, 1992, 359, 67-70.	27.8	773
364	Fractal landscapes in biological systems: Long-range correlations in DNA and interbeat heart intervals. Physica A: Statistical Mechanics and Its Applications, 1992, 191, 1-12.	2.6	66
365	Fractal landscape analysis of DNA walks. Physica A: Statistical Mechanics and Its Applications, 1992, 191, 25-29.	2.6	48
366	Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. American Journal of Cardiology, 1992, 69, 425-427.	1.6	52
367	Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes.. Circulation Research, 1991, 69, 530-539.	4.5	265
368	Post-myocardial infarction risk assessment. Comprehensive Therapy, 1989, 15, 71-6.	0.2	0
369	Coronary vasoconstriction and catecholamine cardiomyopathy. American Heart Journal, 1985, 109, 297-304.	2.7	154
370	Lipomatous hypertrophy of the atrial septum: Diagnosis by combined echocardiography and computerized tornography. American Journal of Cardiology, 1984, 54, 465-466.	1.6	25
371	Effect of Adenosine on Transmural Flow Gradients in Normal Canine Myocardium. Journal of Cardiovascular Pharmacology, 1984, 6, 1115-1119.	1.9	9
372	Adrenomedullin 2 activates extracellular-signal-regulated kinase in endothelial cells via a protein kinase C Î±-independent pathway. F1000Research, 0, 5, 26.	1.6	0